Loading…
Loading…
CID (VictoryShares International High Div Volatility Wtd ETF) is no longer actively trading.
This usually means the fund has been liquidated, merged into another product, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
The fund seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its assets directly or indirectly in the securities included in the Nasdaq Victory International High Dividend 100 Volatility Weighted Index, an unmanaged, volatility weighted index maintained exclusively by the index provider. The index identifies the 100 highest dividend yielding stocks in the Nasdaq Victory International 500 Volatility Weighted Index.
Is CID's expense ratio expensive, average, or a steal for its category?
Pro reveals the verdict on a 5-tier spectrum calibrated against ICI 2025 industry averages, with strategy-aware bands so the comparison is meaningful.
Jaguar's recently completed pivotal effectiveness study of crofelemer for the treatment of CID in dogs demonstrates positive, statistically significant results SAN FRANCISCO, CA / ACCESS Newswire / June 23, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that the company has completed submission of its New Animal Drug Application (NADA) to the U.S. Food and Drug Administration's Center for Veterinary Medicine for full approval of crofelemer for the treatment of chemotherapy-induced diarrhea (CID) in dogs. Crofelemer, under the name Canalevia®-CA1, is currently conditionally approved for this indication in dogs.
Topline results expected within a month and may complement positive results of a study of crofelemer for treatment of cancer therapy-induced diarrhea (CTD) in dogs receiving neratinib - a targeted tyrosine kinase inhibitor (TKI) SAN FRANCISCO, CA / ACCESS Newswire / April 8, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that the Company has completed the company's ongoing effectiveness study of crofelemer delayed-release tablets for the treatment of chemotherapy-induced diarrhea (CID) in dogs. Crofelemer, under the name Canalevia-CA1, is currently conditionally approved for the sole indication of treating CID in dogs.
SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / January 2, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that it received notice from the U.S. Food and Drug Administration's Center for Veterinary Medicine (CVM) on January 1, 2026 that the company has been awarded a $240,000 grant. Canalevia-CA1 is currently conditionally approved for chemotherapy-induced diarrhea (CID) in dogs.
LAS VEGAS--(BUSINESS WIRE)--CID HoldCo, Inc., doing business as Dot Ai (Nasdaq: DAIC) (“Dot Ai” or the “Company”), an IoT and AI-based SaaS company at the forefront of Asset Intelligence technology, today provided an update in response to recent heavy trading activity in its common stock. The Company confirms that it is not aware of any undisclosed material adverse events, has not executed any equity dilution transactions, and has not authorized any sales of Company shares by officers or direct.
Company strategy: In discussions with multiple potential animal health company partners to expand the indication and commercialize Canalevia for treatment of general diarrhea globally SAN FRANCISCO, CA / ACCESS Newswire / September 25, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar"), under its Jaguar Animal Health tradename for the veterinary market, today announced that it has received notice from the U.S. Food and Drug Administration's Center for Veterinary Medicine (CVM) of a $250,000 grant. Canalevia, under the name Canalevia-CA1, is currently conditionally approved for chemotherapy-induced diarrhea (CID) in dogs.